Swine Flu News and Research

RSS
Swine Flu or influenza A (H1N1) is a new flu virus of swine origin that first caused illness in Mexico and the United States in March and April, 2009. It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread, mainly through the coughs and sneezes of people who are sick with the virus, but it may also be spread by touching infected objects and then touching your nose or mouth. Novel H1N1 infection has been reported to cause a wide range of flu-like symptoms, including fever, cough, sore throat, body aches, headache, chills and fatigue. In addition, many people also have reported nausea, vomiting and/or diarrhea.
Government orders additional H1N1 vaccine

Government orders additional H1N1 vaccine

Millions of H1N1 healthcare consent forms - how to manage them?

Millions of H1N1 healthcare consent forms - how to manage them?

PeriGen’s protocol bundle to prevent H1N1 in pregnant women

PeriGen’s protocol bundle to prevent H1N1 in pregnant women

U.S. hospital emergency departments not equipped to care for children

U.S. hospital emergency departments not equipped to care for children

LSA's BCP in place to tackle demand for language assistance in the event of a potential swine flu pandemic

LSA's BCP in place to tackle demand for language assistance in the event of a potential swine flu pandemic

Update from Cannabis Science regarding its phytocannabinoid pharmaceutical products

Update from Cannabis Science regarding its phytocannabinoid pharmaceutical products

U.N. report calls for $1.48B to help developing nations cope with H1N1

U.N. report calls for $1.48B to help developing nations cope with H1N1

Inhalable H1N1 vaccine to arrive in U.S. first week of October, CDC says

Inhalable H1N1 vaccine to arrive in U.S. first week of October, CDC says

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

U.S. Department of Health & Human Services requests BioCryst for proposal for peramivir supply

U.S. Department of Health & Human Services requests BioCryst for proposal for peramivir supply

HHS awards $77.2 million contract to BioCryst to complete Phase 3 development of peramivir

HHS awards $77.2 million contract to BioCryst to complete Phase 3 development of peramivir

Flu Preparedness Program offering latest information on the H1N1 virus

Flu Preparedness Program offering latest information on the H1N1 virus

SmarterTravel releases precautionary checklist for travelers regarding swine flu

SmarterTravel releases precautionary checklist for travelers regarding swine flu

Quidel's updates information on its Influenza A+B test package insert

Quidel's updates information on its Influenza A+B test package insert

BioSante and Cell Genesys encourage stockholders to vote shares

BioSante and Cell Genesys encourage stockholders to vote shares

In Massachusetts, fears about public health vaccination proposal

In Massachusetts, fears about public health vaccination proposal

WHO in talks with developed countries about sharing H1N1 vaccine with developing nations

WHO in talks with developed countries about sharing H1N1 vaccine with developing nations

Mexico fights H1N1 cases with Polycom visual communication systems

Mexico fights H1N1 cases with Polycom visual communication systems

TOWN HALL Los Angeles hosts panel discussion on H1N1 outbreak preparedness

TOWN HALL Los Angeles hosts panel discussion on H1N1 outbreak preparedness

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.